CalciMedica grants director 10,000 stock options

CalciMedica, Inc. (CALC) reported that director Alan Glicklich received a grant of 10,000 Director Stock Options to purchase Common Stock at an exercise price of $0.6131 per share.

Rhea-AI Filing Summary

CalciMedica, Inc. (CALC) reported that director Alan Glicklich received a grant of 10,000 Director Stock Options to purchase Common Stock at an exercise price of $0.6131 per share. The options expire on August 18, 2036 and are scheduled to vest monthly over one year, and in any event be fully vested by the 2027 annual meeting of stockholders.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Glicklich Alan

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Director Stock Option (Right to Buy) F1	10,000	$0.00	$0.00

Holdings After Transaction: Director Stock Option (Right to Buy) — 10,000 contracts (Direct)

Footnotes (1)

1. F1. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

Key Figures

Director Stock Options granted: 10,000 options Exercise price: $0.6131 per share Underlying common shares: 10,000 shares +3 more

6 metrics

Director Stock Options granted 10,000 options Grant to director Alan Glicklich on 2026-08-19

Exercise price $0.6131 per share Exercise price of Director Stock Option grant

Underlying common shares 10,000 shares Common Stock underlying the Director Stock Option

Expiration date 2036-08-18 Option expiration for Director Stock Option grant

Post-transaction option holdings 10,000 options Total Director Stock Options held following the grant

Vesting fraction 1/12 per month Monthly vesting portion over one year after grant date

Key Terms

Director Stock Option (Right to Buy), vesting, annual meeting of stockholders

3 terms

Director Stock Option (Right to Buy) financial

"security_title: Director Stock Option (Right to Buy)"

vesting financial

"1/12th of the shares subject to the option vest in equal monthly"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders regulatory

"fully vested on the date of the 2027 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did CALC disclose for Alan Glicklich?

CalciMedica, Inc. disclosed that director Alan Glicklich received a grant of 10,000 Director Stock Options on August 19, 2026, giving him the right to buy an equal number of CALC common shares at a set exercise price.

What is the exercise price of the new stock options reported by CALC?

The granted Director Stock Options have an exercise price of $0.6131 per share for CalciMedica, Inc. common stock, as specified in the Form 4 filing.

How many CALC shares underlie the options granted to Alan Glicklich?

The option grant to director Alan Glicklich covers 10,000 underlying shares of CalciMedica, Inc. common stock, matching the 10,000 option units awarded.

What is the vesting schedule for Alan Glicklich’s CALC stock options?

The filing states that 1/12th of the shares subject to the option vest in equal monthly installments over one year after the grant date, and the option will in any case be fully vested by the 2027 annual meeting of stockholders.

When do the newly granted CALC stock options expire?

The Director Stock Options granted to Alan Glicklich are scheduled to expire on August 18, 2036, according to the Form 4 disclosure by CalciMedica, Inc.

What is Alan Glicklich’s reported option holding in CALC after this grant?

After the reported transaction, Alan Glicklich holds 10,000 Director Stock Options directly, as indicated by the total shares following the transaction in the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/21/2026 - 06:47 PM EDT Accepted by SEC EDGAR 08/21/2026 - 06:47 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Glicklich Alan

(Last) (First) (Middle)

C/O CALCIMEDICA, INC.

505 COAST S. BLVD, #307

(Street)

LA JOLLA CALIFORNIA 92037

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CalciMedica, Inc. [ CALC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Director Stock Option (Right to Buy)	$0.6131	08/19/2026		A		10,000		(1)	08/18/2036	Common Stock	10,000	$0	10,000	D

Explanation of Responses:

1. 1/12th of the shares subject to the option vest in equal monthly installments over a one year period following the date of grant, provided that the option will in any case be fully vested on the date of the 2027 annual meeting of stockholders of CalciMedica, Inc.

	/s/ John Dunn, Attorney-in-Fact	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)